Development and Commercialization Efforts Sample Clauses

Development and Commercialization Efforts. Corregidor shall, itself or with or through its Affiliates and Collaboration Partners, use Commercially Reasonable Efforts to Develop and Commercialize Licensed Products.

Development and Commercialization Efforts. PMC shall develop, commercialize and market Products using efforts at least comparable to the resources PMC invests in its internally developed priority projects. Without limiting the foregoing, PMC (i) shall conduct such preclinical and clinical trials as are necessary or desirable to obtain all regulatory approvals to develop and commercialize such Products as and where PMC determines are commercially feasible, (ii) shall diligently develop and obtain necessary approval to market such Products (including, as the case may be, pricing approval), and (iii) shall commence marketing and market such Product in each country in which PMC has received all applicable regulatory approvals therefor. PMC shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of such Products, and shall cause its Affiliates and subcontractors to do the same. PMC shall be solely responsible for funding all costs of the development and commercialization of each such Product. PMC shall keep CORIXA informed in a timely manner as to the progress of the development of Products.

Development and Commercialization Efforts. LICENSEE (i) shall use commercially reasonable efforts to diligently conduct such preclinical and clinical trials that are necessary or desirable to obtain all regulatory approvals to develop and commercialize such PRODUCTS, (ii) shall diligently develop and obtain necessary approval to market such PRODUCTS (including, as the case may be, pricing approval), and (iii) shall commence marketing and market such PRODUCTS in each country in which LICENSEE has received all applicable regulatory approvals therefor. LICENSEE shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of such PRODUCTS, and shall cause its Affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for funding all costs of the development and commercialization of each such PRODUCTS.

Development and Commercialization Efforts. LICENSEE shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of PRODUCTS, and shall cause its Affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for funding all costs incurred by LICENSEE for the development and commercialization of each PRODUCT.

Development and Commercialization Efforts. From and after the date hereof, Callisto shall use its commercially reasonable efforts to develop and commercialize at least one drug candidate resulting from the 412 Patent Rights that meet Callisto's criteria for clinical development. Callisto shall have the sole ownership in and to any and all intellectual property rights resulting from Callisto's development efforts (the "Developments"). In the event that HPI exercises its right to terminate this Agreement pursuant to Section 6 by reason of Callisto's material breach of this Section 4.4 or as a result of a determination by Callisto's Board of Directors to abandon its development and commercialization efforts with respect to the 412 Patent Rights, Callisto agrees to grant HPI, on commercially reasonable terms, a non-exclusive license to use any of the Developments that, in the mutual determination of Callisto and HPI, are necessary to enable HPI to develop and commercialize any drug candidates resulting from the 412 Patent Rights.

Development and Commercialization Efforts. From and after the Closing Date, the Purchaser shall use its commercially reasonable efforts to develop and commercialize at least one drug candidate resulting from the 784 Patent Rights that meets the Purchaser's criteria for clinical development. In the event the Board of Directors of the Purchaser shall determine to abandon its development and commercialization efforts with respect to the 784 Patent Rights, the Board of Directors of the Purchaser shall notify the Seller in writing within 10 days of the Board's determination (the "Notice"), and the Seller shall have the right, in its sole discretion, to repurchase the 784 Patent Rights from the Purchaser at a price to be mutually agreed to by the parties in good faith; provided, that such price shall not exceed the fair market value of that portion of the consideration received by the Seller for such patent rights pursuant to this Agreement plus the aggregate amount spent by the Purchaser to maintain the 784 Patent Rights from the Closing Date. In order to exercise its right to repurchase the 784 Patent Rights pursuant to this Section 4.1, the Seller must notify the Purchaser, in writing, of its intent to repurchase within 30 days after receipt of the Notice by the Seller. Any sale or license of the 784 Patent Rights by the Purchaser shall not trigger the Seller's right to repurchase the 784 Patent Rights pursuant to this Section 4.1.

Development and Commercialization Efforts. 3.1.1 deCODE shall exercise diligent efforts at its own cost to have the QT PROLONGATION EVALUATION completed as soon as possible after receipt of COMPOUND and BAYER KNOW HOW according to the timeline and study plan contained in Schedule D. 3.1.2 deCODE shall exercise reasonable development efforts ("reasonable development efforts" shall mean the same degree of diligence that deCODE, in its business judgment, would exercise in pursuing the development and registration of comparable products for comparable indications with comparable sales potential in comparable markets, it being understood that reasonable development efforts will in no event require deCODE to take any action that would be reasonably likely to result in a breach of any other provision of this Agreement or any other agreement to which deCODE is a party existing on the Effective Date, or that deCODE in good faith believes may violate any applicable law, regulation, rule, order, permit, direction or license of any court or governmental authority having appropriate jurisdiction over deCODE) to obtain necessary approvals to market PRODUCT (including, as the case may be, pricing approval). 3.1.3 deCODE shall use reasonable efforts to comply with all applicable Good Laboratory-, Good Clinical- and Good Manufacturing Practices in the development of PRODUCT, and shall commit its AFFILIATES and SUBLICENSEEs and subcontractors to do the same. 3.1.4 To support deCODE in achieving approvals and registrations for clinical trials and PRODUCTS, BAYER will transfer ownership of the BAYER IND and corresponding documents to deCODE effective as of the signature of the Agreement.

Development and Commercialization Efforts. PMC (i) shall use commercially reasonable efforts to diligently conduct such preclinical and clinical trials that are necessary or desirable to obtain all regulatory approvals to develop and commercialize such PRODUCTS, (ii) shall diligently develop and obtain necessary approval to market such PRODUCTS (including, as the case may be, pricing approval), and (iii) shall commence marketing and market such PRODUCTS in each country in which PMC has received all applicable regulatory approvals therefor. PMC shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of such PRODUCTS, and shall cause its Affiliates and subcontractors to do the same. PMC shall be solely responsible for funding all costs of the development and commercialization of each such PRODUCTS. PMC and CISTRON agree to negotiate in good faith PRODUCT development milestones within ninety (90) days following execution of this Agreement.

Development and Commercialization Efforts. (a) In each country in the Territory in which a Product has received Regulatory Approval, Hana, directly or through its permitted Representatives, shall use Commercially Reasonable Efforts to Commercialize the Product and to meet or cause to be met the market demand for the Product. (b) If the University is of the view that Hana is in breach of Section 10.3(a), INEX shall notify Hana and the Parties hereto shall appoint a mutually acceptable person as an independent evaluator (the “Evaluator”) to conduct the evaluation set forth in Section 10.3(c). If the Parties cannot agree on such an evaluator, the appointing authority shall be the British Columbia International Commercial Arbitration Centre. (c) Unless the Parties mutually agree otherwise, the following rules and procedures shall govern the conduct of the Parties and the Evaluator before and during the investigation by the Evaluator: (i) within thirty (30) days of the appointment of the Evaluator, each Party shall provide to the Evaluator and the other Party copies of all documents, statements and records on which the Party intends to rely in presenting its position to the Evaluator; (ii) within forty-five (45) days of the appointment of the Evaluator, Hana shall provide to the Evaluator and INEX a written summary of its position. On receipt of Hana's summary, INEX shall have fifteen (15) days to prepare and submit to Hana and the Evaluator its own summary in reply to the summary submitted by Hana; and (iii) on receipt of the documents, statements, records and summaries submitted by the Parties the Evaluator shall have thirty (30) days within which to conduct such further inquiries as he or she may deem necessary for the purpose of reviewing the efforts made by Hana with respect to the promotion, marketing and sale of the Product in compliance with the requirements of Section 10.3(a). For the purpose of conducting such an inquiry, the Evaluator shall have the right to: (A) require either Party to disclose any further documents or records which the Evaluator considers to be relevant; (B) interview or question either orally (or by way of written questions) one or more Representatives of either Party on issues deemed to be relevant by the Evaluator; (C) make an "on site" inspection of Hana’s facilities; (D) obtain if necessary, the assistance of an independent expert to provide technical information with respect to any area in which the Evaluator does not have a specific expertise. (d) The Evaluator shall...

Development and Commercialization Efforts. LICENSEE shall comply with all applicable and reasonable industry best-practices in the development and commercialization of the products and/or services using the Licensed Technology, and shall cause its affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for all development and commercialization costs. WINTR.4000.01 Page 5 of 25 ___________ ___________ LICENSOR LICENSEE Intellectual Property License And Consulting Agreement